Needham Reiterates Hold on Vertex Pharmaceuticals
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Hold rating on Vertex Pharmaceuticals (NASDAQ:VRTX).
July 26, 2024 | 9:35 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst Joseph Stringer has reiterated a Hold rating on Vertex Pharmaceuticals. This suggests that the analyst does not see significant upside or downside potential in the short term.
The Hold rating indicates that the analyst believes the stock is fairly valued at its current price. This typically suggests limited short-term price movement.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100